RU2017146920A -
METHOD FOR EDITING CCR5 HUMAN GENE WITH THE PURPOSE OF DELTA32 DELETION AT THE EARLY STAGE OF EMBRYONIC DEVELOPMENT
- Google Patents
METHOD FOR EDITING CCR5 HUMAN GENE WITH THE PURPOSE OF DELTA32 DELETION AT THE EARLY STAGE OF EMBRYONIC DEVELOPMENT
Download PDF
Info
Publication number
RU2017146920A
RU2017146920ARU2017146920ARU2017146920ARU2017146920ARU 2017146920 ARU2017146920 ARU 2017146920ARU 2017146920 ARU2017146920 ARU 2017146920ARU 2017146920 ARU2017146920 ARU 2017146920ARU 2017146920 ARU2017146920 ARU 2017146920A
Общество с ограниченной ответственностью "Научно-производственная фирма ДНК-Технология" (ООО "НПФ ДНК-Технология")
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "Научно-производственная фирма ДНК-Технология" (ООО "НПФ ДНК-Технология")filedCriticalОбщество с ограниченной ответственностью "Научно-производственная фирма ДНК-Технология" (ООО "НПФ ДНК-Технология")
Priority to RU2017146920ApriorityCriticalpatent/RU2017146920A/en
Publication of RU2017146920ApublicationCriticalpatent/RU2017146920A/en
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Claims (7)
Способ редактирования гена человека CCR5 с целью внесения делеции delta32 на ранней стадии развития эмбриона человека при помощи системы CRISPR/Cas9 с использованием смеси гидовых РНК с последовательностью:The method of editing the human CCR5 gene to introduce a delta32 deletion at an early stage of human embryo development using the CRISPR / Cas9 system using a mixture of guide RNA with the sequenceCCR5d32_gRNA1:CCR5d32_gRNA1:TAATACGACTCACTATAGGAAGACCTTCTTTTTGAGATCGTTTTAGAGCTAGAAATAGCAAGTAATACGACTCACTATAGGAAGACCTTCTTTTTGGATATGGTTTTAGAGCTAGAAATAGCAAGCCR5d32_gRNA5:CCR5d32_gRNA5:TAATACGACTCACTATAGGACATTAAAGATAGTCATCTTGTTTTAGAGCTAGAAATAGCAAGTAATACGACTCACTATAGGACATTAAAGATAGTCATCTTGTTTTAGAGCTAAATAGCAAGи ДНК-заплатки последовательностью:and DNA patches sequence:GTGATCACTTGGGTGGTGGCTGTGTTTGCGTCTCTCCCAGGAATCATCTTTACCAGATCTCAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACATTAAAGATAGTCATCTTGGGGCTGGTCCTGCCGCTGCTTGTCATGGTCATCTGCTACTCGGGAATCCTAAGTGATCACTTGGGTGGTGGCTGTGTTTGCGTCTCTCCCAGGAATCATCTTTACCAGATCTCAAAAAGAAGGTCTTCATTACACCTGCTCTTCTTTCCATCATTAAAGATAGTCATCTTGGGGTGGTTCTGCCTHTHTHTHTHTHTHTHTTTGTTCGTTCGTTCTTGTTCTTGTTCGTTCGTTCGTTCGTTGTTGTTGGTTGGTTGGTTGGTTGGTGGG
RU2017146920A2017-12-292017-12-29
METHOD FOR EDITING CCR5 HUMAN GENE WITH THE PURPOSE OF DELTA32 DELETION AT THE EARLY STAGE OF EMBRYONIC DEVELOPMENT
RU2017146920A
(en)
rodent, pd-l1 polypeptide, isolated rodent cell or tissue, rodent embryonic stem cell, rodent embryo, and methods for producing a rodent, to reduce tumor growth in a rodent, to kill tumor cells in a rodent rodent to assess the pharmacokinetic properties of a drug and to evaluate the efficacy of a drug.
rodent, humanized lag-3 polypeptide, cell or tissue, embryonic stem cell and rodent embryo, methods for producing a rodent to evaluate the antitumor efficacy and pharmacokinetic properties of a drug
rodent, cd47 polypeptide, isolated rodent cell or tissue, rodent entrepreneurial stem cell, rodent embryo, and methods of producing a rodent, grafting human cells into a rodent, evaluating efficacy therapy of a drug directed to human cells and to evaluate the pharmacokinetic properties, to evaluate the specific and unspecific toxicity of a drug directed to human cd47.
rodent, pd-1 polypeptide, isolated cell or rodent tissue, rodent embryonic stem cell, methods of producing a rodent, reducing tumor growth in a rodent, killing tumor cells in a rodent, and evaluating pharmacokinetic properties of a drug that targets human pd-1, and, rodent tumor model?
genetically modified rodent animal, mouse embryonic stem cell, mouse embryo, and methods for making a rodent animal and grafting human cells into a mouse